“We’ve successfully treated over 100,000 patients”
The Prolieve® Transurethral ThermoDilatation™ Therapy (TUTD™) offers a unique “Thermodilatation” treatment for symptoms of enlarged prostate, also known as benign prostatic hyperplasia (BPH).Prolieve® is the ONLY patented and FDA approved Thermodilatation device on the market.
Prolieve® is a combination therapy simultaneously using Focused Microwave Heating together with Pressurized Balloon Dilatation therapy.
The unique combination treatment is a 45-minute, in-office, outpatient procedure which is performed and well-tolerated under local anesthesia.
Patients do not require a post treatment Foley catheter about 90% of the time. The majority of patients experience significant and immediate relief of their BPH symptoms.
Our Prolieve TUTD Advantages Over Other Minimally-Invasive BPH Therapies
|Proven Immediate Symptom Relief & Long-Term Safety, Efficacy & Durability||Yes|
|Appealing to Patients: Fewer Post-Treatment Catheterization||Yes|
|No Foreign Bodies or Clips left within the Urinary Tract||Yes|
|No Puncture of Plastic Urethra to minimize Pain & Hemorrhage||Yes|
|No/Minimal Sexual Side Effects (E.D. & Retrograde Ejaculation)||Yes|
|Rectal Temperature Monitoring for Added Safety to the rectum & neurovascular bundles||Yes|
FDA Post Approval 5-Year Follow-up Study Completed & Accepted “Prevention of BPH Progression By Stabilizing PSA & Prostate Volume”
|Post-Treatment Catheter-Free Rate||85%|
|Stabilization of BPH Symptoms||83% reported No Progression at Year 5|
|Erectile Dysfunction/Retrograde Ejaculation||0.3 per 100 person-years|
|Significant Improvement of Mean AUA Symptom Score||Baseline = 20.1 vs. Year 5 = 12.8|
|Significant Improvement of Peak Flow Rate (Qmax)||Baseline = 8.6 mL/s vs. Year 5 = 12.8 mL/s|
|Significant Improvement of Quality of Life (QOL) Score||Baseline = 22 vs. Year 5 = 16|